Hostname: page-component-7bb8b95d7b-qxsvm Total loading time: 0 Render date: 2024-09-16T10:00:48.827Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Studies on the Effect of Imuran and Vincristine in the Treatment of Leukaemia

Published online by Cambridge University Press:  01 August 2014

E. Storti ,
A. Traldi  and
D. Quaglino
E. Storti
Affiliation:
Istituto di Patologia Medica dell'Università, Modena
A. Traldi
Affiliation:
Istituto di Patologia Medica dell'Università, Modena
D. Quaglino
Affiliation:
Istituto di Patologia Medica dell'Università, Modena

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The Authors describe the therapeutic effects obtained with Vincristine and Imuran in patients with acute leukaemia.

The results obtained with Vincristine indicate that the drug may be usefully employed in some cases of lymphoblastic leukaemia, both in the untreated phase or when the disease has become resistant to other antimetabolites. The remissions are of shorter duration compared with those obtained with other available compounds and are substantially confined to the lymphoblastic variety of acute leukaemia.

The preliminary clinical trial with Imuran has shown that the drug is better tolerated than 6-mercaptopurine and is able to produce good and satisfactory remissions in lymphoblastic and myeloblastic leukaemia, as well as in the blastic crisis of chronic granulocytic leukaemia, provided the dosage employed reaches 7-8 mg/Kg body weight daily.

Type
Research Article
Information
Acta geneticae medicae et gemellologiae: twin research , Volume 17 , Issue 1 , January 1968 , pp. 220 - 231
Copyright
Copyright © The International Society for Twin Studies 1968

References

Bibliographie

Bohannon, R. A. et al. (1962). Leurocristine in the treatment of lymphomas and leukaemias. Proc. Amer. Assoc. Cancer Res., 3: 305.Google Scholar
Carbone, P., Brindley, C. O. (1962). Clinical studies with leurocristine. Proc. Amer. Assoc. Cancer Res., 3: 309.Google Scholar
Cardinali, G. et al. (1961). The stathmokinetic effect of vincaleukoblastine on normal bone-marrow and leukaemic cells. Cancer Res., 21: 1542.Google Scholar
Cardinali, G. et al. (1963). Studies on the antimitotic activity of Leurocristine (Vincristine). Blood, 21: 102.Google Scholar
Costa, G. et al. (1962). Clinical studies with leurocristine. Proc. Amer. Assoc. Cancer Res., 3: 312.Google Scholar
Elion, G. B. et al. (1961). A summary of investigations with 6-((I-methyl-4-nitro-5-imidazolyl)thio)purine (B. W. 57-322). Cancer Chemother. Rep., 14: 93.Google Scholar
Hitchings, G. H., Elion, G. B. (1959). Activity of heterocyclic derivatives of 6-mercaptopurine and 6-thioguanine in adenocarcinoma 755. Proc. Amer. Assoc. Cancer Res., 3: 27.Google Scholar
Johnson, I. S. et al. (1963). The Vinca alkaloids: a new class of oncolytic agents. Cancer Res., 23: 1390.Google Scholar
Karon, M. et al. (1962). III. A preliminary report on vincristine sulfate. A new active agent for the treatment of acute leukaemia. Pediatrics, 30: 791.Google Scholar
Rundles, R. W. et al. (1961). Clinical and hematologic study of 6-((I-methyl-4-nitro-5-imidazolyl)thio)purine (B. W. 57-322) and related compounds. Cancer Chemother. Rep., 14: 99.Google Scholar
Schwartz, R. et al. (1958). Effect of 6-mercaptopurine (6-MP) on antibody production. Proc. Soc. Exp. Biol. Med., 99: 164.Google Scholar
Storti, E. et al. (1963). L'impiego della Vincaleucoblastina nella terapia del linfogranuloma maligno. Minerva Med., 54: 1789.Google Scholar
Zukoski, C. F., Callaway, J. M. (1962). Effect of B.W. 57.322, 6-methyl-mercaptopurine, Urethane plus 6-azauracil, and prednisolone on renal homografts survival. Fed. Proc., 21: 30.Google Scholar